We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
-11.79%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
AUM
$227M
AUM Growth
-$29.8M
Cap. Flow
+$9.22M
Cap. Flow %
4.06%
Top 10 Hldgs %
39.83%
Holding
81
New
31
Increased
12
Reduced
7
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$10.7M
2
AZN icon
AstraZeneca
AZN
+$8.94M
3
EHC icon
Encompass Health
EHC
+$8.33M
4
CTLT
CATALENT, INC.
CTLT
+$8.19M
5
DHR icon
Danaher
DHR
+$7.6M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$14.5M
2
DXCM icon
DexCom
DXCM
+$13.1M
3
AMED
Amedisys
AMED
+$10.8M
4
SNY icon
Sanofi
SNY
+$9.54M
5
VAR
Varian Medical Systems, Inc.
VAR
+$8.52M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Energy 3.09%
3 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PFNX
51
DELISTED
Pfenex Inc.
PFNX
$750K 0.33%
+85,000
New +$934K
A icon
52
Agilent Technologies
A
$42B
-170,000
Closed -$14.5M
ABBV icon
53
AbbVie
ABBV
$440B
-95,000
Closed -$8.41M
AMED
54
DELISTED
Amedisys
AMED
-65,000
Closed -$10.8M
AMRN
55
Amarin Corp
AMRN
$295M
-8,750
Closed -$2.91M
APLS
56
DELISTED
Apellis Pharmaceuticals
APLS
-35,000
Closed -$1.07M
BHC icon
57
Bausch Health
BHC
$2.31B
-100,000
Closed -$2.99M
BLUE
58
DELISTED
bluebird bio
BLUE
-2,702
Closed -$3.07M
CI icon
59
Cigna
CI
$72.2B
-10,000
Closed -$2.04M
CVS icon
60
CVS Health
CVS
$120B
-100,000
Closed -$7.43M
DTIL icon
61
Precision BioSciences
DTIL
$210M
-1,667
Closed -$695K
DXCM icon
62
DexCom
DXCM
$33.7B
-240,000
Closed -$13.1M
GH icon
63
Guardant Health
GH
$22.3B
-70,000
Closed -$5.47M
GOSS icon
64
Gossamer Bio
GOSS
$88.6M
-60,000
Closed -$938K
HOLX
65
DELISTED
Hologic
HOLX
-30,000
Closed -$1.57M
INCY icon
66
Incyte
INCY
$24.4B
-25,000
Closed -$2.18M
IRTC icon
67
iRhythm Holdings
IRTC
$4.04B
-20,000
Closed -$1.36M
LLY icon
68
Eli Lilly
LLY
$1.07T
-50,000
Closed -$6.57M
NBIX icon
69
Neurocrine Biosciences
NBIX
$16.1B
-15,000
Closed -$1.61M
NKTR icon
70
Nektar Therapeutics
NKTR
$2.56B
-5,000
Closed -$1.62M
QURE icon
71
uniQure
QURE
$3.15B
-55,000
Closed -$3.94M
SNY icon
72
Sanofi
SNY
$104B
-190,000
Closed -$9.54M
TFX icon
73
Teleflex
TFX
$5.88B
-21,000
Closed -$7.91M
THC icon
74
Tenet Healthcare
THC
$21.1B
-75,000
Closed -$2.85M
VTRS icon
75
Viatris
VTRS
$18.6B
-130,000
Closed -$2.61M

Similar funds

Integral Health Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Integral Health Asset Management held 81 positions worth $227M, down 12% from $257M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Integral Health Asset Management deployed $9.22M of net new capital in Q1 2020, opening 31 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 136,240 shares worth $10M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Energy and Consumer Discretionary.

On the sell side, the largest reduction was Humana, an estimated $6.07M trimmed.

  • Integral Health Asset Management's largest Q1 2020 buy was Merck: 136,240 shares worth $10M.
  • Integral Health Asset Management added most to ChemoCentryx, Inc. in Q1 2020, an estimated $5.94M increase.
  • Integral Health Asset Management's biggest Q1 2020 reduction was Humana, cutting an estimated $6.07M.
  • Integral Health Asset Management fully exited Agilent Technologies in Q1 2020, selling an estimated $14.5M.
  • Integral Health Asset Management's ten largest holdings make up 40% of its $227M portfolio in Q1 2020.
  • Integral Health Asset Management opened 31 new positions and closed 30 in Q1 2020.
  • Integral Health Asset Management's portfolio value fell 12% quarter-over-quarter to $227M.

Based on Integral Health Asset Management's 13F filing for Q1 2020, filed 15 May 2020.